This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1. LP Celentano , Resurgence of pertussis in Europe. Pediatric Infectious Disease Journal 2005; 24: 761–765.
2. B Ntezayabo , G de Serres , B Duval . Pertussis resurgence in Canada largely caused by a cohort effect. Pediatric Infectious Disease Journal 2003; 22: 22–27.
5. SC de Greeff , Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatric Infectious Disease Journal 2008; 27: 218–223.
6. D Guris , Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clinical Infectious Diseases 1999; 28: 1230–1237.
7. DM Skowronski , The changing age and seasonal profile of pertussis in Canada. Journal of Infectious Diseases 2002; 185: 1448–1453.
8. KM Bisgard , Infant pertussis: who was the source? Pediatric Infectious Disease Journal 2004; 23: 985–989.
9. E Elliott , National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatric Infectious Disease Journal 2004; 23: 246–252.
10. AM Wendelboe , Transmission of Bordetella pertussis to young infants. Pediatric Infectious Disease Journal 2007; 26: 293–299.
11. SA Halperin . Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatric Infectious Disease Journal 2005; 24: S141–S146.
12. T Tan , E Trindade , D Skowronski . Epidemiology of pertussis. Pediatric Infectious Disease Journal 2005; 24: S10–S18.
13. SC de Greeff , Pertussis disease burden in the household: how to protect young infants. Clinical Infectious Diseases 2010; 50: 1339–1345.
18. HW Hethcote , P Horby , P McIntyre . Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004; 22: 2181–2191.
19. A Van Rie , HW Hethcote . Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22: 3154–3165.
21. M van Boven , Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Mathematical Biosciences 2000; 164: 161–182.
24. T Jefferson , M Rudin , C DiPietrantonj . Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21: 2003–2014.
26. JR Casey , ME Pichichero . Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005; 65: 1367–1389.
27. JE Frampton , SJ Keam . Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation: use as a single-dose booster immunization in adolescents aged 10–18 years. Paediatric Drugs 2006; 8: 189–195.
28. JI Ward , Efficacy of an acellular pertussis vaccine among adolescents and adults. New England Journal of Medicine 2005; 353: 1555–1563.
29. HE de Melker , The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. Journal of Infection 2006; 53: 106–113.
32. J Mossong , Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Medicine 2008; 5: e74.
34. A van Rie , AM Wendelboe , JA Englund . Role of maternal pertussis antibodies in infants. Pediatric Infectious Disease Journal 2005; 24: S62–S65.
35. RM Anderson , RM May . Infectious Diseases of Humans. Oxford: Oxford University Press, 1991.